| Description: |
Theophylline is a competitive nonselective phosphodiesterase inhibitor and nonselective adenosine receptor antagonist, which is the most widely used anti-asthma drug worldwide and is classified as a bronchodilator. It has antiinflammatory, and immunomodulatory actions, it also can antagonize flurazepam-induced depression of cerebral cortical neurons. |
| Targets: |
gp120/CD4 | TNF-α | IL Receptor | cAMP | HDAC |
| In vitro: |
| Eur J Pharm Sci. 2015 May 6. | | The formulation of a pressurized metered dose inhaler containing theophylline for inhalation.[Pubmed: 25956075] | Theophylline (TP) is a bronchodilator used orally to treat Chronic Obstructive Pulmonary Disease (COPD) that has been associated with multiple side effects, tempering its present use. This study aims to improve COPD treatment by creating a low-dose pressurized metered dose inhaler (pMDI) inhalable formulation of Theophylline.
METHODS AND RESULTS:
Aerosol performance was assessed using Andersen Cascade Impaction (ACI). Solubility of Theophylline in HFA 134/ethanol mixture was measured and morphology of the particles analyzed with a Scanning Electron Microscope (SEM). Calu-3 cell viability, epithelial cell transport and inflammatory-response assays were conducted to study the impact of the formulation on lung epithelial cells. The mass deposition profile of the formulation showed an emitted dose of 250.04±14.48μg per 5 actuations, achieving the designed nominal dose (50μg/dose). SEM showed that the emitted particles were hollow with spherical morphology. Approximately 98% of Theophylline was transported across Calu-3 epithelial cells and the concentration of interleukin-8 secreted from Calu-3 cells following stimulation with tissue necrosis factor-α (TNF-α) resulted in significantly lower level of interleukin-8 released from the cells pre-treated with Theophylline (1.92±0.77ngml-1 Theophylline treated vs. 8.83±2.05ngml-1 TNF-α stimulated, respectively).
CONCLUSIONS:
The solution pMDI formulation of Theophylline developed in present study was shown to be suitable for inhalation and demonstrated anti-inflammatory effects at low doses in Calu-3 cell model. |
|
| In vivo: |
| J Exp Med. 2004 Sep 6; 200(5): 689–95. | | Theophylline Restores Histone Deacetylase Activity and Steroid Responses in COPD Macrophages[Pubmed: 15337792] | Chronic obstructive pulmonary disease (COPD) is a common chronic inflammatory disease of the lungs with little or no response to glucocorticoids and a high level of oxidative stress. Histone deacetylase (HDAC) activity is reduced in cells of cigarette smokers, and low concentrations of Theophylline can increase HDAC activity.
METHODS AND RESULTS:
We measured the effect of Theophylline on HDAC activity and inflammatory gene expression in alveolar macrophages (AM) from patients with COPD. AM from normal smokers showed a decrease in HDAC activity compared with normal control subjects, and this was further reduced in COPD patients (51% decrease, P < 0.01). COPD AMs also showed increased basal release of IL-8 and TNF-α, which was poorly suppressed by dexamethasone. Theophylline induced a sixfold increase in HDAC activity in COPD AM lysates and significantly enhanced dexamethasone suppression of induced IL-8 release, an effect that was blocked by the HDAC inhibitor trichostatin A.
CONCLUSIONS:
Therefore, Theophylline might restore steroid responsiveness in COPD patients. | | J Basic Clin Physiol Pharmacol. 2015 Apr 18. | | Comparative study of the efficacy and safety of theophylline and doxofylline in patients with bronchial asthma and chronic obstructive pulmonary disease.[Pubmed: 25894641] | Bronchial asthma and chronic obstructive pulmonary disease (COPD) are the major obstructive disorders that may contribute to the severity in individual patients. The present study was designed to compare the efficacy and safety of Theophylline and doxofylline in patients with bronchial asthma and COPD.
METHODS AND RESULTS:
A total of 60 patients, 30 each with bronchial asthma and COPD, were enrolled for the study. Each group of 30 patients received standard treatment for asthma and COPD. Each group was again subdivided into two with 15 patients each, who received Theophylline or doxofylline in addition to standard therapy, for a period of 2 months. Each patient was followed up fortnightly for the assessment of efficacy parameters using a pulmonary function test (PFT), clinical symptoms and emergency drug use, and safety was assessed by recording adverse drug reactions. Both Theophylline and doxofylline produced enhancements in PFT at different time intervals in both asthma and COPD patients. The maximum beneficial effects were seen at 6 weeks for asthma patients and at 8 weeks for COPD patients for both Theophylline and doxofylline.
CONCLUSIONS:
The comparative study showed that doxofylline was more effective as evidenced by improvement in PFT as well as clinical symptoms, and reduced incidence of adverse effects and emergency bronchodilator use. |
|
Cell. 2018 Jan 11;172(1-2):249-261.e12. doi: 10.1016/j.cell.2017.12.019.IF=36.216(2019)
Cell Metab. 2020 Mar 3;31(3):534-548.e5. doi: 10.1016/j.cmet.2020.01.002.IF=22.415(2019)
Mol Cell. 2017 Nov 16;68(4):673-685.e6. doi: 10.1016/j.molcel.2017.10.022.IF=14.548(2019)
ACS Nano. 2018 Apr 24;12(4): 3385-3396. doi: 10.1021/acsnano.7b08969.IF=13.903(2019)
Nature Plants. 2016 Dec 22;3: 16206. doi: 10.1038/nplants.2016.205.IF=13.297(2019)
Sci Adv. 2018 Oct 24;4(10): eaat6994. doi: 10.1126/sciadv.aat6994.IF=12.804(2019)
